PAVmed Inc. (PAVM)
NASDAQ: PAVM · Real-Time Price · USD
0.4856
+0.0359 (7.98%)
At close: Oct 7, 2025, 4:00 PM EDT
0.5199
+0.0343 (7.06%)
Pre-market: Oct 8, 2025, 4:14 AM EDT
PAVmed Revenue
PAVmed had revenue of $6.00K in the quarter ending June 30, 2025, a decrease of -99.39%. This brings the company's revenue in the last twelve months to $1.02M, down -73.36% year-over-year. In the year 2024, PAVmed had annual revenue of $3.00M with 22.15% growth.
Revenue (ttm)
$1.02M
Revenue Growth
-73.36%
P/S Ratio
6.29
Revenue / Employee
$26,154
Employees
39
Market Cap
10.32M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3.00M | 543.00K | 22.15% |
Dec 31, 2023 | 2.45M | 2.08M | 550.40% |
Dec 31, 2022 | 377.00K | -123.00K | -24.60% |
Dec 31, 2021 | 500.00K | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
PAVM News
- 20 hours ago - PAVmed Subsidiary, Veris Health and The Ohio State University Comprehensive Cancer Center Launch Commercial Phase of Strategic Partnership Agreement - PRNewsWire
- 21 days ago - Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs - PRNewsWire
- 26 days ago - Lucid Diagnostics Announces Closing of Public Offering of Common Stock - PRNewsWire
- 27 days ago - Lucid Diagnostics Announces Pricing of Public Offering of Common Stock - PRNewsWire
- 4 weeks ago - Lucid Diagnostics Announces Proposed Public Offering of Common Stock - PRNewsWire
- 4 weeks ago - Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025 - PRNewsWire
- 5 weeks ago - Lucid Diagnostics to Participate in the Cantor Global Healthcare Conference 2025 - PRNewsWire
- 6 weeks ago - PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology - PRNewsWire